Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Pottermore and Storytel make multi-language production of the Hogwarts Library books

Pottermore and Storytel will work together to produce and distribute the Harry Potter series called the Hogwarts Library books in several new languages. The collection contains three stories: Fantastic Beasts and Where to Find Them, Quidditch Through the Ages and The Tales of Beedle the Bard.Since 2016, Storytel has been cooperating with Pottermore to distribute the Harry Potter series for subscribers all over the world. Now Storytel and Pottermore take their next step together by producing the Hogwarts Library books for audio. The productions will be released in ten different languages,

Invitation to Saab’s Sensor Seminar: Sensors - for a Safer World

Saab is pleased to invite media, financial analysts and investors to our Sensor Seminar, on 24th February 2022, 14:00 CET.The Sensor Seminar will be hosted by Carl-Johan Bergholm, Head of Saab´s business area Surveillance. The seminar will provide an insight on the journey to meet and counter the threats and challenges of modern warfare. This year’s seminar will demonstrate Saab’s take on current sensor development for today’s defence forces, on electronic warfare in a multi-domain environment and on how to get the deceptive advantage with electronic attack capabilities. We will also

NEW RECOMMENDATION BY THE MINISTRY OF HEALTH OF THE RUSSIAN FEDERATION: All patients with suspected gastritis should be examined by Pepsinogen I, Pepsinogen II and Gastrin-17 biomarkers.

Biohit Oyj press release                                 15.2.2022 at 10.00 local time (EEST) In December 2021, the Ministry of Health of the Russian Federation made public new official clinical guidelines on the diagnostic practices to be followed for all patients with suspected gastritis or duodenitis (1). According to these new guidelines, “all patients with suspected precancerous changes in the stomach with gastritis (atrophy, intestinal metaplasia) in order to confirm the diagnosis, assess the risk of developing gastric cancer and determine the order of endoscopic observation is

Outokumpu receives the highest Platinum level sustainability recognition from EcoVadis

Outokumpu OyjPress releaseFebruary 15, 2022 at 10.00 EETOutokumpu receives the highest Platinum level sustainability recognition from EcoVadis Outokumpu has received the highest Platinum level recognition for the second year in a row from the sustainability rating platform EcoVadis. The Platinum level rating indicates that Outokumpu is among the top 1% of the over 85,000 companies evaluated. “We are happy to continue on the highest Platinum level in the EcoVadis rating and to be among the top 1% sustainability performers. We have made good progress in sustainability and launched

SMART WIRES OUTPERFORMS FULL-YEAR 2021 REVENUE, TRIPLING GROWTH FROM 2020

· Full-year 2021 revenue of approximately $47.5 Million; >3x growth over 2020; exceeds guidance of $38 to $42 million · Fourth quarter 2021 revenue of approximately $19.2 Million · Company issues 2022 revenue guidance in the range of $65M - $70MSmart Wires Technology Ltd. (NASDAQ 1[st] North: GOGRID-SDB.ST), a global power technology company that is advancing the delivery of affordable, clean electricity worldwide today announced its fourth quarter and 2021 full-year revenue results and issued 2022 revenue guidance. Fourth Quarter and 2021 Revenue Preliminary, unaudited fourth

BioStock: Aptahem’s Q4 lays groundwork for clinical studies

During the last quarter of 2021, Aptahem took further steps towards being able to initiate phase I clinical studies with the drug candidate Apta-1 in 2022, primarily by initiating production of GMP-certified drug substance. At the beginning of January, this was followed up by a signed start up agreement with an international clinical contract research organisation for the clinical development phase.Read the full article at biostock.se: https://www.biostock.se/en/2022/02/aptahems-q4-lays-groundwork-for-clinical-studies/ This is a press release from BioStock - Connecting Innovation &

BioStock: BiBBInstruments kicks off 2022 with capital raise

After reaching a key clinical milestone with EndoDrill Model X in deep tumours of the upper gastrointestinal tract at the end of 2021, BiBBInstruments is looking to expand its clinical programme into both existing and new cancer indications in 2022. In preparations for this, the company has announced raising 21.6 MSEK in a directed share issue. BioStock spoke with BiBB’s CEO Fredrik Lindblad to get his thoughts.Read the full interview with BiBBInstrument's CEO Fredrik Lindblad at biostock.se: https://www.biostock.se/en/2022/02/bibbinstruments-kicks-off-2022-with-capital-raise/ This is

Hynion AS 2021 Annual report

“2021 was a breakthrough year for Hynion. We raised capital, listed on Euronext Growth, explored exciting next-generation technologies and started expanding our station network. Our project pipeline supports our target of eight stations in Norway and Sweden by the end of 2022, followed by further expansion in Scandinavia and Europe.  We have in 2021 become the leading hydrogen refueler in Norway and Sweden,” says Ulf Hafseld, CEO of HynionSignificant events during the financial year Hynion is delivering on station development and volumes are increasing · Hynion has four established

Sleep Cycle year end report 2021: Increased net sales and new product launches

Net sales increased 15.0% to SEK 48.0m during the fourth quarter, corresponding to a 21.7% currency adjusted growth rate. During the quarter several new features were launched which, in combination with effective campaigns, lead to positive sales development. The total amount of subscriptions increased 14.3% to 901k. The subscription growth rate increased compared to last year (10.1%) but, due to negative foreign exchange impact, the volume growth was not fully reflected in revenues.Fourth quarter summary (October-December 2021) · Net sales increased by 15.0 % (23.0 % October-December

2021 Year-end report

A strong finish sums up a successful year With an order intake on par with Alelion's previous record year, we are showing that the long-term effort to transform the business is paying off. We enter the new year with a total order backlog amounting to MSEK 138. During the fourth quarter, order intake increased to MSEK 57, which allows us to sum up 2021 as one of Alelion's best years ever with an order intake totaling MSEK 184.The fouth quarter 2021 in brief · Net sales increased to MSEK 9.3 (8.5) · Order intake increased to MSEK 57.0 (1.8) · Operating costs for personnel, other

MEDIVIR AB – YEAR-END REPORT JANUARY – DECEMBER 2021

Significant progress, both in the clinical program and in our business developmentOctober – December Financial summary for the quarter · Net turnover amounted to SEK 13.9 (1.5) million. · The loss before interest, tax, depreciation and amortization (EBITDA) amounted to SEK -23.5 (-10.6) million. Basic and diluted earnings per share amounted to SEK -0.44 (-0.46) and SEK -0.44 (-0.46) respectively. · Cash flow from operating activities amounted to SEK -5.4 (-1.0) million. · Liquid assets and short-term investments at the end of the period amounted to SEK 221.2 (70.0) million.

Ratos company Aibel receives extension of Equinor frame agreement

Equinor has decided to exercise a contract option for maintenance and modifications services on the Norwegian Continental Shelf (NCS). Aibel estimates that the value of the extension is approx. NOK 5.5 billion. Aibel will work on continuous improvements, digitalization of processes, and contribute to a sustainable development of the NCS.Aibel's frame agreements with Equinor for maintenance and modifications comprise work on ten offshore installations and five onshore facilities, and the agreements constitute a major part of Aibel's activities. The current agreements expire at the end of

Norway Royal Salmon ASA (NRS): Publishing preliminary financial figures for the fourth quarter of 2021

NRS has today published preliminary financial figures for the 4th quarter of 2021 which are attached to this stock exchange announcement. Headlines for the 4th quarter of 2021: The group's total operating revenues in the fourth quarter of 2021 amounted to NOK 1 495.5 million. This resulted in an operational EBIT for the fourth quarter of 2021 of NOK 101.6 million, while profit before tax in the fourth quarter of 2021 was NOK -10.7 million. Final figures for the fourth quarter will be presented in connection with NRS's quarterly reporting on 23 February 2022. The final figures may

Notice to Exel Composites Plc’s Annual General Meeting 2022

EXEL COMPOSITES PLC      STOCK EXCHANGE RELEASE      15 FEBRUARY 2022 at 09:15 EETNotice is given to the shareholders of Exel Composites Plc to the Annual General Meeting of Shareholders to be held on Friday 25 March 2022 at 09:30 EET in Exel Composites’ premises at Mäkituvantie 5, 01510 Vantaa, Finland. Shareholders of the company may participate in the meeting and exercise their shareholders’ rights only through a proxy representative and by submitting counterproposals and questions in advance. Proxy representatives must see to the voting in advance on behalf of shareholders. Instructions

Merger plan signed with Lundin Energy

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, HONG KONG OR JAPAN, OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. THIS ANNOUNCEMENT DOES NOT CONSTITUTE AN OFFER OF ANY OF THE SECURITIES DESCRIBED HEREIN. Reference is made to the stock exchange notice published by Aker BP ASA (“Aker BP”) on 21 December 2021 whereby it announced that Aker BP and Lundin Energy AB (“Lundin Energy”) had entered into a transaction agreement pursuant to which Aker BP and

New framework agreement for automation solutions in life science

Semcon has signed a new framework agreement as supplier to Graniten. The agreement, which runs indefinitely, covers services in robot programming, electrical design, mechanical design and validation.Graniten is a global product supplier in pharmaceutical and healthcare automation and offers products ranging from custom innovations to full-scale production equipment. The company is based on business and technological innovation and currently collaborates with a number of major partners within the pharmaceutical industry and lab automation. “This is a very interesting collaboration for us

Kemira Oyj: Announcement of manager’s transaction; President and CEO Jari Rosendal has purchased 5,000 Kemira shares

Kemira Oyj, Managers' transactions, February 15, 2022 at 9.05 am (EET)Kemira Oyj: Announcement of manager’s transaction; President and CEO Jari Rosendal has purchased 5,000 Kemira shares Kemira has received a notification from Jari Rosendal, President and CEO, of a transaction made with its financial instrument, according to the EU Market Abuse Regulation.Detailed information about the transaction is given below.Person subject to the notification requirement:Name: Rosendal, JariPosition: Chief Executive OfficerIssuer: KEMIRA LEI: 74370031Y7RK5H88CQ48Notification type:

Lynparza combo delays progression risk in prostate

15 February 2022 07:00 GMT Lynparza plus abiraterone reduced risk of disease progression by 34% vs. standard-of-care in 1st-line metastatic castration-resistant prostate cancer Combination was well tolerated and allowed patients to maintain their quality of life vs. patients treated with abiraterone alone PROpel Phase III trial results show clinically meaningful benefit in patients irrespective of homologous recombination repair gene mutations Positive results from the PROpel Phase III trial showed AstraZeneca and MSD's Lynparza (olaparib) in combination with abiraterone

Axolot Solutions Holding AB (publ) - Year-end report January-December 2021

Focus on cost efficient, sustainable holistic solutions, handling a larger flow range.Summary of the fourth quarter 2021 Financially · Net sales amounted to 586 tSEK (1 318 tSEK for the corresponding quarter in 2020), which refers to customer trial activities and studies. In the comparison period 2020, one AxoPur® system was sold. · Other revenues were 22 tSEK (286), which relates to public research grants and project support. · Earnings before interest and tax became -4 822 tSEK (-3 953). · Net earnings per share amounted to -0,09 SEK (-0,15). · Liquid funds were 12 868

Notice of 2021 Full Year Results

15 February 2022 Gulf Keystone Petroleum Ltd. (LSE: GKP) ("Gulf Keystone", "GKP" or "the Company") Notice of 2021 Full Year Results Gulf Keystone confirms that the Company's results for the year ended 31 December 2021 will be announced on Wednesday 30 March 2022. The management team will host a presentation for analysts and investors via live audio webcast which will be available on the Company's website. Enquiries: Gulf Keystone: +44 (0) 20 7514 1400  Aaron Clark, Head of Investor Relations aclark@gulfkeystone.com Celicourt Communications:

Aiforia signs agreement with South Korean biotech company to augment its novel drug discovery platform with AI

Aiforia and Genuv will collaborate to to integrate Aiforia’s deep learning AI into Genuv’s ATRIVIEW® discovery platform for neurodegenerative diseases.The two companies announced an agreement to add Aiforia’s artificial intelligence technology to Genuv’s ATRIVIEW® proprietary drug discovery platform, used to screen both existing drugs and new substances for neuroprotective and neuroregenerative effects. ATRIVIEW® was used to discover Genuv’s leading drug candidate, SNR1611, which has shown the ability to restore CNS function in preclinical models of amyotrophic lateral sclerosis (ALS) and

Exel Composites' Financial Statements Release Q1-Q4 2021: Revenue increased significantly, profitability declined

EXEL COMPOSITES PLC    FINANCIAL STATEMENTS RELEASE    15 FEBRUARY 2022 at 09:00 EETQ4 2021 in brief  · Order intake decreased by 8.8% to EUR 30.5 million (Q4 2020: 33.4).  · Revenue increased by 32.7% to EUR 36.5 million (27.5).  · Operating profit decreased to EUR 0.6 million (2.7), which is 1.8% of revenue (9.9). · Adjusted operating profit decreased to EUR 1.0 million (2.7), which is 2.8% of revenue (9.9).  · Earnings per share amounted to EUR 0.04 (0.09). Q1-Q4 2021 in brief  · Order intake increased by 21.8% to EUR 140.6 million (Q1-Q4 2020: 115.4).  ·

Entrepreneurs Carl Douglas and Anders Böös, together with Johanna Mattsson, want to give the world the cleanest filtered drinking water using Swedish Nordaq’s technology

Byline: Zap PR  Nordaq is a premium water that delivers the purest filtered water to 0.3 microns, which no other global water company is currently able to offer.   Nordaq started as a sustainability project to find a way to be able to drink the same water wherever you are in the world, and thus to offer a premium bottled water that tastes pure, without any transportation.   Transporting water over water is one of the most illogical things we can do because we automatically shrink our own source and make it harder to get clean water because we pollute the soil.

Sivers Semiconductors AB (publ), Year-End Report January – December 2021

Fourth quarter 2021 · Revenue amounted to SEK 23.390 M (29.707), a decrease of 21% · Profit before depreciation and amortization (EBITDA) amounted to SEK -23.422 M (3.108) · Operating profit/loss (EBIT) for the quarter was SEK -33.223 M (-4.632) · Profit/loss after tax was SEK -25.108 M (-0.563) · Earnings per share before and after dilution was SEK -0.15 (0.00) · Equity per share amounted to SEK 4.57 (3.41) · Profit for the quarter was negatively affected by acquisition costs of SEK 4.186 M.January- December 2021: · Revenue amounted to SEK 90.652 M (96.170), a

There are no items matching the current filter
There are no more items matching the current filter
Back to top